SCHEMBL31247692

SCHEMBL31247692

Cc1cccc(Nc2cc(Nc3ccccc3C#N)ncn2)n1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 2/20 0.47
▸ SYK P43405 3/20 0.47
▸ GRM5 P41594 6/20 0.47
▸ IRAK4 Q9NWZ3 1/20 0.46
▸ JAK2 O60674 2/20 0.42
▸ JAK1 P23458 2/20 0.42
▸ TYK2 P29597 2/20 0.42
▸ JAK3 P52333 2/20 0.42
▸ MAP4K4 O95819 1/20 0.42
▸ GSK3B P49841 1/20 0.42
▸ BACE1 P56817 1/20 0.40
▸ LRRK2 Q5S007 1/20 0.39
▸ EGFR P00533 1/20 0.39
▸ ERBB3 P21860 1/20 0.39
▸ KDR P35968 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31247670 0.86 SYK (0.48) AURKASYKGRM5IRAK4JAK2
SCHEMBL31247586 0.85 GRM5 (0.44) AURKASYKGRM5IRAK4JAK2
SCHEMBL31247717 0.85 GRM5 (0.44) AURKASYKGRM5IRAK4JAK2
SCHEMBL31247770 0.85 AURKA (0.43) AURKASYKGRM5IRAK4JAK2
SCHEMBL31247588 0.84 AURKA (0.55) AURKAIRAK4JAK2JAK1JAK3
SCHEMBL31247617 0.82 AURKA (0.57) AURKAIRAK4LRRK2EGFRKDR
SCHEMBL31247703 0.82 GRM5 (0.48) SYKGRM5JAK2JAK1TYK2
SCHEMBL31247576 0.82 GRM5 (0.55) GRM5BACE1NPC1RAB9ASMN1; SMN2
SCHEMBL31247548 0.81 AURKA (0.48) AURKAJAK2JAK1TYK2MAP4K4
SCHEMBL15679618 0.77 SYK (0.46) SYKGRM5LRRK2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719394-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2026-04-08 — — EP disclosed
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE ATOMWISE INC (US) 2026-02-19 — — US disclosed
US-12358904-B2 Inhibitors of TYK2 Atomwise Inc. (US) 2025-07-15 — — US disclosed
US-20240425484-A1 INHIBITORS OF TYK2 Atomwise Inc. 2024-12-26 — — US disclosed
US-20240417396-A1 INHIBITORS OF TYK2 Atomwise Inc. 2024-12-19 — — US disclosed
WO-2024250010-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2024-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240417396-A1 INHIBITORS OF TYK2 TYK2, LCK, JAK2 AURKA 150/4885SYK 11/4885GRM5 2396/4885
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE TYK2, FRK, DYRK2 AURKA 1353/4885SYK 33/4885GRM5 1437/4885
US-12358904-B2 Inhibitors of TYK2 TYK2, LCK, JAK2 AURKA 150/4885SYK 11/4885GRM5 2396/4885
US-20240425484-A1 INHIBITORS OF TYK2 TYK2, LCK, JAK2 AURKA 150/4885SYK 11/4885GRM5 2396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback